Abstract: A pharmaceutical composition comprised of a crystalline protein and polyethylene glycol or vegetable oil and a process for producing the same.
Type:
Grant
Filed:
December 14, 1994
Date of Patent:
December 21, 1999
Assignee:
Schering Corporation
Inventors:
Paul Reichert, Alan W. Hruza, Nagamani Nagabushan, Tattanahalli Nagabhushan
Abstract: Stably-transformed human cell lines containing a reporter gene operatively linked to an IL-4-responsive element are provided. In some embodiments a human Fc.sub..epsilon. RII IL-4-responsive element is used. In other embodiments a human germline .epsilon. transcript promoter is used as the responsive element. Also provided are methods for using such transformed cell lines to screen for agonists and/or antagonists of human interleukin-4.
Type:
Grant
Filed:
May 30, 1995
Date of Patent:
September 28, 1999
Assignee:
Schering Corporation
Inventors:
Jan E. de Vries, Chung-Her Jenh, Satwant K. Narula, Paul J. Zavodny
Abstract: Mammalian proteins and muteins thereof, designated interleukin-4s (IL-4s), are provided which exhibit both B cell growth factor activity and T cell growth factor activity. Compounds of the invention include native human and murine IL-4s, muteins thereof, and nucleic acids which are effectively homologous to disclosed cDNAs, and/or which are capable of coding for mammalian IL-4s and their muteins.
Type:
Grant
Filed:
June 6, 1995
Date of Patent:
September 21, 1999
Assignee:
Schering Corporation
Inventors:
Frank Lee, Takashi Yokota, Ken-ichi Arai, Timothy Mosmann, Donna Rennick
Abstract: Hybrid regulatory proteins are provided which contain amino acid sequences that are susceptible to cleavage by specific proteolytic enzymes. When acted upon by such enzymes, the hybrid regulatory proteins are rendered substantially less active, thereby altering the rate of production of products of indicator genes that are controlled by the regulatory proteins. Also provided are DNAs encoding such regulatory proteins, recombinant vectors and transformed eukaryotic cells containing such DNAs, and methods for identifying inhibitors of the specific proteolytic enzymes.
Abstract: Transformed cell lines containing a reporter gene operatively linked to a genetic control element that is responsive to growth factor-stimulated cell proliferation and/or oncogene-mediated neoplastic transformation are provided. Also provided are methods for using such transformed cell lines to screen for growth factor antagonists and/or antineoplastic agents.
Abstract: This invention relates to the use of IL-10, alone or in combination with IL-2 and/or .alpha.-IFN, to treat neoplastic disorders by stimulating cytolytic activity of peripheral blood mononuclear cells with IL-10 alone.
Abstract: Monoclonal antibodies are provided which are specific for human interleukin-4. Also provided are complementary DNAs which encode the heavy and light chain variable regions of such monoclonal antibodies and complementarity determining regions from such DNAs; and kits and methods for detecting, measuring and immunopurifying human interleukin-4, and for blocking the biological activity of human interleukin-4.
Type:
Grant
Filed:
August 16, 1994
Date of Patent:
January 26, 1999
Assignee:
Schering Corporation
Inventors:
Barbara Dalie, Hung V. Le, Kenneth Miller, Nicholas J. Murgolo, Hanh Nguyen, Stephen Tindall, Paul J. Zavodny
Abstract: The present invention provides isolated human and bovine TNF-.alpha. convertases, nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods for making the convertases using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the convertases and are useful for treating medical conditions caused or mediated by TNF-.alpha.. Also provided are screening methods for identifying specific inhibitors of mammalian TNF-.alpha. convertases, and for identifying nucleic acids encoding such convertases.
Type:
Grant
Filed:
July 10, 1997
Date of Patent:
December 29, 1998
Assignee:
Schering Corporation
Inventors:
Barbara Dalie, Xuedong Fan, Daniel Lundell, Charles A. Lunn, Jimmy C. Tan, Paul J. Zavodny
Abstract: A method is provided for toting a B cell mediated autoimmune disorder comprising administering an effective amount of an interleukin-10 antagonist.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
November 17, 1998
Assignee:
Schering Corporation
Inventors:
Rene De Waal Malefyt, Maureen Howard, Di-Hwei Hsu, Hiroshi Ishida, Anne O'Garra, Hergen Spits, Albert Zlotnik
Abstract: A method is provided for reducing an inflammatory response in a mammal comprising administering to a mammal at risk of developing or afflicted with an inflammatory response characterized by substantially elevated levels of IL-1.alpha., IL-1.beta., IL-6, IL-8 and TNF.alpha., an amount of IL-10 effective to substantially lower the levels of such cytokines.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
November 17, 1998
Assignee:
Schering Corporation
Inventors:
Rene De Waal Malefyt, Maureen Howard, Di-Hwei Hsu, Hiroshi Ishida, Anne O'Garra, Hergen Spits, Albert Zlotnik
Abstract: Disclosed is a method for treating an individual who is predisposed to develop insulin-dependent diabetes mellitus. To practice the method, an amount of interleukin-10 protein effective to maintain blood glucose levels at a non-diabetic level is administered to an individual predisposed to develop the disease.
Type:
Grant
Filed:
March 30, 1995
Date of Patent:
October 27, 1998
Assignee:
Schering Corporation
Inventors:
Martha W. Bond, Kevin W. Moore, Kenneth Pennline, Paulo J. M. Vieira
Abstract: Mammalian proteins and muteins thereof, designated interleukin-4s (IL-4s), are provided which exhibit both B cell growth factor activity and T cell growth factor activity. Compounds of the invention include native human and murine IL-4s, muteins thereof, and nucleic acids which are effectively homologous to disclosed cDNAs, and/or which are capable of coding for mammalian IL-4s and their muteins.
Type:
Grant
Filed:
June 6, 1995
Date of Patent:
September 15, 1998
Assignee:
Schering Corporation
Inventors:
Frank Lee, Takashi Yokota, Ken-ichi Arai, Timothy Mosmann, Donna Rennick
Abstract: A method is provided for using interleukin-10 in adoptive immunotherapy of cancer. A population of tumor-infiltrating lymphocytes (TILs) are expanded in culture in the presence of interleukin-2 (IL-2) and interleukin-10 (IL-10). After administration of the TILs to a patient, effective amounts of both IL-2 and IL-10 are administered to enhance the tumor cell cytoxicity of the TILs and to reduce side effects caused by IL-2-induced cytokine production in the TILs and other cells of the patient.
Type:
Grant
Filed:
July 5, 1994
Date of Patent:
July 7, 1998
Assignee:
Schering Corporation
Inventors:
Di-Hwei Hsu, Kevin W. Moore, Hergen Spits
Abstract: A method is provided for treating acute leukemias, e.g. acute myelogenous leukemia and acute lymphocytic leukemia. The method comprises administering to a mammal a therapeutically effective amount of interleukin-10.
Type:
Grant
Filed:
June 27, 1996
Date of Patent:
June 23, 1998
Assignee:
Schering Corporation
Inventors:
.O slashed.ystein Bruserud, Mary Ellen M. Rybak
Abstract: Monoclonal antibodies are provided which are specific for human interleukin-4. Also provided are complementary DNAs which encode the heavy and light chain variable regions of such monoclonal antibodies and complementarity determining regions from such DNAs; and kits and methods for detecting, measuring and immunopurifying human interleukin-4, and for blocking the biological activity of human interleukin-4.
Type:
Grant
Filed:
June 6, 1995
Date of Patent:
June 23, 1998
Assignee:
Schering Corporation
Inventors:
Barbara Dalie, Hung V. Le, Kenneth Miller, Nicholas J. Murgolo, Hanh Nguyen, Stephen Tindall, Paul J. Zavodny
Abstract: This invention provides materials and methods for identifying inhibitors of a Hepatitis C Virus NS3 protein ATPase. Methods for making and purifying such an ATPase are also provided by this invention.
Abstract: A method is provided for treating or preventing inflammatory conditions, in particular septic shock and inflammatory conditions caused by auto-immune diseases, such as inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis, uveitis, and psoriasis. The method comprises administering to a mammal a therapeutically effective amount of IL-10 plus at least one steroid such as betamethasone. Also provided are pharmaceutical compositions and kits comprising IL-10 plus at least one steroid, e.g., betamethasone or its derivatives.